Navigation Links
Wyeth to Present at the SG Cowen & Co. 29th Annual Healthcare Conference
Date:3/12/2009

MADISON, N.J., March 12 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) announced today that it will present at the SG Cowen & Co. 29th Annual Healthcare Conference on Tuesday, March 17, 2009 at 9:30 a.m. Eastern Time. Presenting for Wyeth will be Mikael Dolsten, M.D., Ph.D., President, Wyeth Research and Senior Vice President, Wyeth.

Wyeth's presentation will be webcast live for investors at www.wyeth.com and available for replay following the conference.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products, and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to our proposed merger with Pfizer, including satisfaction of the conditions of the proposed merger on the proposed timeframe or at all, contractual restrictions on the conduct of our business included in the merger agreement, and the potential for loss of key personnel, disruption in key business activities or any impact on our relationships with third parties as a result of the announcement of the proposed merger; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; the outcome of government investigations; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; global economic conditions; interest and currency exchange rate fluctuations and volatility in the credit and financial markets; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on February 27, 2009. The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE Wyeth
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
2. Wyeth Names Michael Kamarck President, Technical Operations & Product Supply
3. Wyeth Declares Preferred Stock Dividend
4. Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
5. Wyeth Wins Philadelphia Diet Drug Trial Involving Claim of PPH
6. Wyeth Announces Increase in Common Stock Dividend
7. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
8. Wyeth Sets Webcast And Conference Call for 2008 Third Quarter Earnings
9. Cyprus and Ireland Add Wyeths 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
10. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
11. Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... , June 14, 2017   Micralyne Inc., ... and a primary supplier of sensors, is pleased ... Placentia, California to develop and ... (TSV).  The joint development of this technology leverages ... a truly flexible and cost effective Metal TSV ...
(Date:6/14/2017)... ... June 13, 2017 , ... ... the phenotype of an organism on a molecular level that is closely ... processing remain major bottlenecks to biomarker discovery in clinical-based metabolomics research. , ...
(Date:6/13/2017)... ... June 13, 2017 , ... Three ... Phase 1 Ventures (P1V) program. PolyCeramX, Recensa Therapeutics and Regennera, all P1V participants, ... , Phase 1 Ventures is a startup accelerator that helps launch and ...
(Date:6/13/2017)... PA and London UK (PRWEB) , ... June 13, 2017 , ... ... for Information and Study on Clinical Trial Participation (CISCRP) and the Society for Clinical ... Expert speakers will provide background on the purpose of eConsent and the ability for ...
Breaking Biology Technology:
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
(Date:3/22/2017)... VILNIUS, Lithuania , March 21, 2017 /PRNewswire/ ... identification and object recognition technologies, today announced the ... development kit (SDK), which provides improved facial recognition ... safety cameras on a single computer. The new ... algorithms to improve accuracy, and it utilizes a ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel visited ... to the DERMALOG stand together with the Japanese Prime Minster Shinzo Abe. ... the largest German biometrics company the two government leaders could see the ... well as DERMALOGĀ“s multi-biometrics system.   Continue Reading ... ...
Breaking Biology News(10 mins):